Clinical approval of the immune checkpoint blockade (ICB) agents for multiple cancer types
has reinvigorated the long-standing work on cancer vaccines. In the pre-ICB era, clinical …

Therapeutic cancer vaccines have gained significant popularity in recent years as new
approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines …

Current excitement about cancer immunotherapy is the result of unprecedented clinical
impact from immune checkpoint inhibitors, particularly those that target programmed death …

Tumor vaccines have been an attractive concept in the immunotherapy of cancer based on
the central role of tumor-associated antigens in allowing the immune system to recognize …

This comprehensive review delves into the rapidly evolving arena of cancer vaccines.
Initially, we examine the intricate constitution of the tumor microenvironment (TME), a …

Therapeutic cancer vaccines have proven to seldom induce dramatic clinical response
when used alone, and therefore, they are being studied in combination with additional …

Cancer vaccines and immune checkpoint inhibitors (ICIs) function at different stages of the
cancer immune cycle due to their distinct mechanisms of action. Therapeutic cancer …

The promise of immune-based therapies to treat cancer has been realized over the last
several years with several breakthrough therapies, including T-cell checkpoint inhibitors and …

With the spotlight on cancer immunotherapy and the expanding use of immune checkpoint
inhibitors, strategies to improve the response rate and duration of current cancer …

Dramatic success in cancer immunotherapy has been achieved over the last decade with
the introduction of checkpoint inhibitors, leading to response rates higher than with …